We can’t show the full text here under this license. Use the link below to read it at the source.
A narrative review on tirzepatide’s therapeutic potential in glycemic control and cardioprotection
Tirzepatide's potential to improve blood sugar control and heart health
AI simplified
Abstract
Tirzepatide reduced glycated hemoglobin () by up to 2.5% and body weight by more than 20%.
- Tirzepatide is a new dual receptor agonist for treating type 2 diabetes and obesity.
- It improved cardiovascular risk factors, including blood pressure and lipid levels.
- Patients with heart failure with preserved ejection fraction and obstructive sleep apnea experienced reductions in the apnea-hypopnea index and hospitalizations for heart failure.
- The safety profile aligns with other GLP-1 receptor agonists, though gastrointestinal issues and potential thyroid cancer signals require monitoring.
- Ethical concerns exist regarding off-label use and weight regain after stopping the medication.
AI simplified
Key numbers
2.46%
Reduction
Reduction achieved with tirzepatide 15 mg vs. semaglutide 1 mg.
11.2 kg
Weight Loss
Average weight loss with tirzepatide 15 mg in SURPASS-2.
38%
Cardiovascular Event Reduction
Relative risk reduction in heart failure hospitalizations with tirzepatide.